Summary
University College London (UCL), a subsidiary of University of London is an educational institute that provides educational programs in arts and humanities, medicine, engineering, and science. The university’s faculties include arts and humanities, Bartlett faculty of the built environment, brain sciences, engineering, laws, life sciences, mathematical and physical sciences, medical sciences, population health sciences and social, and historical sciences. It offers services such as alumini services, infrastructure management, finance and business affairs, human resource development, information services, library services, public and cultural engagement, and student and registry services. UCL is headquartered in London, the UK.
University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
University College London, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
University College London, Medical Devices Deals, 2010 to YTD 2016 11
University College London, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
University College London, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 16
Canbex Therapeutics Raises US$3 Million In Venture Financing 17
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 19
UCL Business Raises US$71 Million In First Round Financing 21
Partnerships 22
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 22
Teva Pharma Partners with University College London and Imanova 24
University College London Enters into Research Agreement with Takeda Pharma 25
Takeda Enters into R&D Agreement with University College London 26
iQur Enters into Co-Development Agreement with Six Consortium 27
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 29
Cellectis Enters Into Co-Development Agreement With University College London 30
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 31
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 32
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 33
TAP Biosystems Enters Into Co-Development Agreement With University College London 34
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 36
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 38
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 39
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 40
Eisai Enters Into Research Agreement With University College London 41
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 42
PolyTherics Enters Into Collaboration With University College London 44
AstraZeneca Enters Agreement With UCL Business To Develop Regenerative Medicines For Diabetic Retinopathy 45
AstraZeneca Enters Into Co-Development Agreement With University College London 47
Licensing Agreements 48
Autolus Enters into Licensing Agreement with UCL Business 48
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 49
Oxford Pharmascience Extends Licensing Agreement With UCL Business 50
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 51
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 53
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 54
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 55
AbD Serotec Enters Into An Agreement With UCL Business 56
University College London - Key Competitors 57
Key Employees 58
Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
List of Tables
University College London, Pharmaceuticals & Healthcare, Key Facts 1
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University College London, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University College London, Deals By Therapy Area, 2010 to YTD 2016 10
University College London, Medical Devices Deals, 2010 to YTD 2016 12
University College London, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 13
Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 17
Canbex Therapeutics Raises US$3 Million In Venture Financing 18
Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round 20
UCL Business Raises US$71 Million In First Round Financing 22
Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 23
Teva Pharma Partners with University College London and Imanova 25
University College London Enters into Research Agreement with Takeda Pharma 26
Takeda Enters into R&D Agreement with University College London 27
iQur Enters into Co-Development Agreement with Six Consortium 28
Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 30
Cellectis Enters Into Co-Development Agreement With University College London 31
Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 32
Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 33
Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 34
TAP Biosystems Enters Into Co-Development Agreement With University College London 35
Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 37
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 39
UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics 40
UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus 41
Eisai Enters Into Research Agreement With University College London 42
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 43
PolyTherics Enters Into Collaboration With University College London 45
AstraZeneca Enters Agreement With UCL Business To Develop Regenerative Medicines For Diabetic Retinopathy 46
AstraZeneca Enters Into Co-Development Agreement With University College London 48
Autolus Enters into Licensing Agreement with UCL Business 49
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 50
Oxford Pharmascience Extends Licensing Agreement With UCL Business 51
BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 52
Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 54
University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 55
UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies 56
AbD Serotec Enters Into An Agreement With UCL Business 57
University College London, Key Competitors 58
University College London, Key Employees 59
University College London, Subsidiaries 60
List of Figures
University College London, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
University College London, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
University College London, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
University College London, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
University College London, Medical Devices Deals, 2010 to YTD 2016 12
